Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 4.

Journal Article

Moskowitz, C., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N., Ribrag, V., Radford, J., von Tresckow, B., Tomita, A., Shipp, M., Wang, Y., Ricart, A. D., Balakumaran, A. and Chen, R. (2016). PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: MULTICOHORT, PHASE 2 KEYNOTE-087 STUDY. Haematologica, 101. S. 44 - 45. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Moskowitz, C., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N., Ribrag, V., Radford, J., von Tresckow, B., Tomita, A., Shipp, M. A., Wang, Y., Ricart, A. D., Balakumaran, A. and Chen, R. (2016). MULTICOHORT PHASE 2 STUDY OF PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-087. Haematologica, 101. S. 319 - 320. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Zinzani, P. L., Sasse, S., Radford, J., Gautam, A. and Bonthapally, V. (2016). Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. Crit. Rev. Oncol./Hematol., 104. S. 65 - 71. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-0461

Zinzani, P. L., Sasse, S., Radford, J., Shonukan, O. and Bonthapally, V. (2015). Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. Crit. Rev. Oncol./Hematol., 95 (3). S. 359 - 370. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-0461

This list was generated on Fri Mar 29 13:23:11 2024 CET.